PerspectivePublished 12 October 2026Precision targeting of type 2 inflammation in COPD: identifying candidates for dupilumab therapyKezhuo Zhong · Kaiying Lv · Qun LiangFrontiers in Pharmacologydoi 10.3389/fphar.2026.1971309
PerspectivePublished 8 October 2026From disease activity scores to precision medicine: biomarkers and composite models for risk stratification in chronic spontaneous urticariaShuayb Elkhalifa · Mohamed AbuzakoukFrontiers in Allergydoi 10.3389/falgy.2026.1962595
Systematic ReviewPublished 7 October 2026Biologics and JAK inhibitors for atopic manifestations in inborn errors of immunity: a systematic reviewMahnaz Jamee · Roba Maher Al-Gaweesh · Amirhossein Hajialigol · Sally Gouda Mohammed · Peyman Tirandazi · Abdullah A. Alangari · Rasha El-OwaidyFrontiers in Allergydoi 10.3389/falgy.2026.1867183
Case ReportPublished 18 September 2026Case Report: Multisystem response to dupilumab in a child with atopic dermatitis, asthma, eosinophilic esophagitis, and other gastrointestinal manifestationsHua-Jie Yan · Wei Dong · Yu-Nan Yang · Chun-Yun ZengFrontiers in Allergydoi 10.3389/falgy.2026.1929466
Systematic ReviewPublished 11 September 2026New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapyBaozhu Huang · Yue Xu · Ye Tian · Xiaoyu Liu · Xiaoyu Gao · Xue Wang · Yurong Zhang · Xiaoman Li · Ting Liu · Weibang Chen · Wenya Gao · Huikuan Chen · Feng Li · Danxian Jiang · Junfeng Hao · Chunjie TianFrontiers in Allergydoi 10.3389/falgy.2026.1903649
ReviewPublished 9 September 2026Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthmaB. Jentzsch · A. Hoheisel · K. Gashynova · S. Fähndrich · B. C. Frye · J. A. Alvarado Castillo · S. Müller · I. Cherrez-Ojeda · D. StolzFrontiers in Allergydoi 10.3389/falgy.2026.1942188
Case ReportPublished 31 August 2026Case Report: Successful dupilumab treatment for refractory atopic dermatitis-like eczema in a patient with Costello syndromeToshihiko Nonaka · Jun Kido · Mika Ogata · Taiga Miyake · Takanobu Yoshida · Satoshi Fukushima · Rie Seyama · Yuri Uchiyama · Naomichi Matsumoto · Kimitoshi NakamuraJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2026.17346
Original ResearchPublished 25 June 2026Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis: a 24- and 48-week cohort from ColombiaJhon Bolaños-López · Carlos Bello · Luz. E. Pérez · Farley González · Sergio Londoño · Yuri Torres · Alejandra ToroFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1838972
Letter to the EditorPublished 5 February 2026Exacerbation of hand rash after dupilumab initiation in a child with atopic dermatitis who was able to continue treatmentKanoko Kono · Takashi Sakai · Yutaka HatanoJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2026.16078
Science archivePublished 9 July 2025Real-world safety and effectiveness of dupilumab for the treatment of atopic dermatitis: two-year post-marketing surveillance in JapanHidehisa Saeki · Makiko Usami · Katsuhisa Suzuki · Michika Mochizuki · Kazuhiko ArimaJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.14794
Science archivePublished 10 June 2025An open-label interventional clinical study evaluating sweating function in dupilumab treatment for atopic dermatitisMai Matsumoto · Yuta Koike · Motoi Takenaka · Hiroyuki MurotaJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.14517
Science archivePublished 28 April 2025Successful treatment of familial cases of epidermolysis bullosa pruriginosa with dupilumabMaya Kaga · Yasushi Suga · Akira IshikoJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.14677
LupusPublished 5 November 2024Monoclonal antibodies targeting type 2 inflammation in eosinophil-associated diseases during pregnancy: insights from two eosinophilic granulomatosis with polyangiitis cases and a comprehensive literature reviewFederica Davanzo · Luca Iorio · Antonia Calligaro · Andrea Doria · Roberto PadoanFrontiers in Lupusdoi 10.3389/flupu.2024.1479884